Celularity is a clinical-stage biotechnology company developing off-the-shelf allogeneic cell therapies derived from the postpartum placenta to treat cancer, infectious diseases, and age-related conditions. The company's platform leverages placental-derived cellular sources including natural killer (NK) cells, T cells, and mesenchymal stromal cells.
Celularity is publicly traded
This company is no longer available on our private secondary market. Shares can be traded publicly under its listed ticker.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2016
Employees
120–126
Total Funding
$333.4M
2 rounds
Latest Valuation
$1.29B
January 8, 2021
Total raised $333.4M across 2 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
PIPE (concurrent with SPAC merger)
Date
January 8, 2021
Amount
$83.4M
Valuation
$1.29B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| January 8, 2021 | PIPE (concurrent with SPAC merger) | $83.4M | $1.29B | Not disclosed |
| February 15, 2018 | Series A / Formation financing | $250M | — | Not disclosed |
Robert J. Hariri
Founder, Chairman, and Chief Executive Officer
John R. Haines
Senior Executive Vice President, General Manager, and Chief Administrative Officer
Brad Glover
Executive Vice President and Chief Operating Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Fate Therapeutics
Clinical-stage biotech developing off-the-shelf CAR NK immunotherapies from iPSC-derived cells, including FT576 targeting BCMA.
Dragonfly Therapeutics
Developing TriNKETs platform-based NK cell therapies to engage innate and adaptive immune systems.
ONK Therapeutics
Gene-edited NK cell therapy company with CAR NK candidates for AML, multiple myeloma, and solid tumors.
Artiva Biotherapeutics
Developing off-the-shelf NK cell therapies as an alternative to CAR-T with improved safety profile.
Celularity went public via SPAC merger with GX Acquisition Corp., with the combined company commencing trading on Nasdaq Capital Market under ticker CELU on July 19, 2021. As of May 2026, the stock trades below $1.05 with a market capitalization of approximately $28-36M.
Celularity shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker to place an order.
Celularity had a valuation of approximately $1.29B at the time of its public offering. Current market capitalization fluctuates with the share price.
Celularity raised $333.4M across 2 disclosed funding rounds prior to its public listing.
Celularity was founded by Robert J. Hariri in 2016.
Celularity is headquartered in Florham Park, NJ, United States.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.